Biomerica, Inc. (NASDAQ: BMRA). According to a recent study and poster published by Fabiane B. Klem, M.D., of the Universidade Federal do Parana, approximately one in nine people develop irritable bowel syndrome within a year of an intestinal infection. The International Foundation for Functional Gastrointestinal Disorders which states that there are up to 45 million IBS sufferers in the United States.
Many of the existing treatments on the market only address one form of IBS (IBS-C: constipation or IBS-D: diarrhea), and produce side effects that are equally as challenging for patients to manage as IBS itself.
Biomerica’s product (InFoods® IBS), is a simple blood test that identifies the body’s reactions to specific foods, as opposed to food groups, allowing medical staff to provide therapeutic guidance on which foods should be removed from a patient’s diet to alleviate symptoms.
The company will be presenting at the 9th annual LD Micro Main Event on Wednesday, December 7 at 7:30 AM PST / 10:30 AM EST at the Luxe Sunset Boulevard Hotel in Los Angeles.
